Covered recipient · General Payments record
MOHIT NARANG
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$196,200.02
268 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $111,167.00 | 40 |
| Consulting Fee | $37,828.75 | 21 |
| Travel and Lodging | $32,349.08 | 53 |
| Food and Beverage | $7,280.59 | 145 |
| Honoraria | $7,254.50 | 5 |
| Long term medical supply or device loan | $299.10 | 3 |
| Education | $21.00 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 2 of 6; records 51–100 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MOHIT NARANG
NPI 1881695351 · CMS profile ID 39457
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
OWING MILLS, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1881695351?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MOHIT NARANG, NPI 1881695351, CMS profile ID 39457. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881695351?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MOHIT NARANG, NPI 1881695351, CMS profile ID 39457. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881695351?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MOHIT NARANG, NPI 1881695351, CMS profile ID 39457, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1881695351?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
268 matching records · $196,200.02 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 268.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $137.70 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699731 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.42 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014136489 | CMS |
| Celgene Corporation | $20.24 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643243 | CMS |
| E.R. Squibb & Sons, L.L.C. | $103.91 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643263 | CMS |
| E.R. Squibb & Sons, L.L.C. | $493.24 | 10/18/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643267 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,176.00 | 10/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643643 | CMS |
| Janssen Biotech, Inc. | $425.00 | 10/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699705 | CMS |
| Janssen Biotech, Inc. | $137.39 | 10/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699735 | CMS |
| Pharmacosmos Therapeutics Inc. | $3,000.00 | 10/17/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257541 | CMS |
| Janssen Biotech, Inc. | $850.00 | 10/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699723 | CMS |
| Novartis Pharmaceuticals Corporation | $25.47 | 10/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992904399 | CMS |
| Seagen Inc. | $28.00 | 10/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995730487 | CMS |
| GENZYME CORPORATION | $38.34 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049918969 | CMS |
| Pharmacosmos Therapeutics Inc. | $104.99 | 10/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257533 | CMS |
| Pharmacosmos Therapeutics Inc. | $32.13 | 10/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257525 | CMS |
| E.R. Squibb & Sons, L.L.C. | $88.42 | 10/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643635 | CMS |
| Janssen Biotech, Inc. | $5.50 | 10/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699717 | CMS |
| Janssen Biotech, Inc. | $5.50 | 10/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699721 | CMS |
| E.R. Squibb & Sons, L.L.C. | $112.84 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643275 | CMS |
| E.R. Squibb & Sons, L.L.C. | $585.58 | 10/05/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643279 | CMS |
| Daiichi Sankyo Inc. | $28.16 | 10/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006516099 | CMS |
| Rigel Pharmaceuticals, Inc. | $110.00 | 10/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033443675 | CMS |
| Rigel Pharmaceuticals, Inc. | $3,744.00 | 10/04/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033443725 | CMS |
| Janssen Biotech, Inc. | $1,100.00 | 10/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988699715 | CMS |
| Janssen Pharmaceuticals, Inc | $16.24 | 09/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988611689 | CMS |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 09/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643639 | CMS |
| BeiGene USA, Inc. | $411.63 | 09/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051187569 | CMS |
| BeiGene USA, Inc. | $87.34 | 09/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051187575 | CMS |
| Novartis Pharmaceuticals Corporation | $24.99 | 09/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992904395 | CMS |
| Pharmacosmos Therapeutics Inc. | $39.70 | 09/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257517 | CMS |
| E.R. Squibb & Sons, L.L.C. | $51.85 | 09/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643229 | CMS |
| BeiGene USA, Inc. | $22.26 | 09/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051187579 | CMS |
| Seagen Inc. | $4,375.00 | 09/18/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995730619 | CMS |
| Pharmacosmos Therapeutics Inc. | $500.00 | 09/12/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257505 | CMS |
| Genentech USA, Inc. | $22.91 | 09/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040478083 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.04 | 09/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999324151 | CMS |
| Pharmacosmos Therapeutics Inc. | $1,529.50 | 09/05/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257495 | CMS |
| Celgene Corporation | $2,400.00 | 08/30/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643671 | CMS |
| PFIZER INC. | $20.32 | 08/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050038379 | CMS |
| Adaptive Biotechnologies Corporation | $14.31 | 08/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1022975227 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28.66 | 08/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643213 | CMS |
| Amgen Inc. | $649.00 | 08/25/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020644521 | CMS |
| Pharmacosmos Therapeutics Inc. | $709.05 | 08/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257477 | CMS |
| Pharmacosmos Therapeutics Inc. | $109.63 | 08/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046257485 | CMS |
| AVEO Pharmaceuticals, Inc. | $91.73 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049063069 | CMS |
| Daiichi Sankyo Inc. | $727.50 | 08/23/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006607247 | CMS |
| Novartis Pharmaceuticals Corporation | $18.47 | 08/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992904389 | CMS |
| Celgene Corporation | $200.59 | 08/18/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643675 | CMS |
| Celgene Corporation | $124.92 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015643189 | CMS |
| Seagen Inc. | $817.50 | 08/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995730607 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $167,355.52 | 109 |
| PY2024 | Principal investigator | $313,750.73 | 145 |
| PY2023 | Principal investigator | $513,428.13 | 200 |
| PY2022 | Principal investigator | $363,274.38 | 157 |
| PY2021 | Principal investigator | $468,059.94 | 253 |
| PY2020 | Principal investigator | $710,998.15 | 224 |
| PY2019 | Recipient | $11,416.00 | 2 |
| PY2019 | Principal investigator | $902,480.27 | 205 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
109 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $4,500.00 | 12/29/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549098 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663830 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663842 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,844.90 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663854 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663858 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663876 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663878 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663882 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663886 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663888 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663892 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663894 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663900 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663912 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 12/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663926 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549104 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549109 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549117 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549123 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549129 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549135 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549141 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 11/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549159 |
| Principal investigator 1 | Celgene Corporation | $5,851.00 | 10/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222304541 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 10/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549147 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 10/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1240549153 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663816 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663822 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663824 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663828 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663836 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663846 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663848 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,844.90 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663852 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663856 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663860 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663864 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663870 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,844.90 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663874 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663884 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663896 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663904 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 10/02/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663908 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $88.99 | 09/30/2025 | Non-covered Recipient Entity Maryland Oncology Hematology Columbia | A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) | No dispute reported | 06/30/2026 | 1235996099 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549045 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549062 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549068 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549074 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549081 |
| Principal investigator 1 | Incyte Corporation | $125.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549087 |
| Principal investigator 1 | Incyte Corporation | $666.00 | 09/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549092 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 09/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663832 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 09/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663880 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,488.65 | 09/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663898 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663818 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663820 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663834 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663838 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663844 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,488.65 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663862 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,938.95 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663866 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663868 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663890 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663906 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663910 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 08/04/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663914 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,000.00 | 07/25/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235931067 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 07/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549050 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 07/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1240549056 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,997.95 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663826 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $95.00 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663850 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $191.00 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663872 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $62.00 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663916 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663918 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,479.15 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663922 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $215.00 | 07/03/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663924 |
| Principal investigator 1 | Celgene Corporation | $15,224.48 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222305604 |
| Principal investigator 1 | Incyte Corporation | $125.00 | 06/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549003 |
| Principal investigator 1 | Incyte Corporation | $476.00 | 06/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549026 |
| Principal investigator 1 | Incyte Corporation | $476.00 | 06/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549032 |
| Principal investigator 1 | Incyte Corporation | $125.00 | 06/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549038 |
| Principal investigator 1 | Celgene Corporation | $1,500.00 | 05/21/2025 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. | No dispute reported | 06/30/2026 | 1222304521 |
| Principal investigator 1 | Novocure Inc. | $1,000.00 | 05/08/2025 | Non-covered Recipient Entity US Oncology Research, LLC | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856471 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,310.00 | 04/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1235996087 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 04/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1240549008 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 04/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549014 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 04/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240549020 |
| Principal investigator 1 | Novocure Inc. | $850.00 | 04/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856653 |
| Principal investigator 1 | Novocure Inc. | $1,000.00 | 04/11/2025 | Non-covered Recipient Entity US Oncology Research, LLC | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856749 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,125.00 | 03/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211681216 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $19,689.00 | 03/17/2025 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1235992203 |
| Principal investigator 1 | Incyte Corporation | $476.00 | 03/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548956 |
| Principal investigator 1 | Incyte Corporation | $125.00 | 03/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548961 |
| Principal investigator 1 | Incyte Corporation | $125.00 | 03/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548967 |
| Principal investigator 1 | Incyte Corporation | $861.00 | 03/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548985 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $5,261.00 | 03/06/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663902 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $235.00 | 02/07/2025 | Non-covered Recipient Entity US Oncology Research, LLC | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211681210 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $4,500.00 | 02/03/2025 | Non-covered Recipient Entity Us Oncology Res Llc | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530290 |
| Principal investigator 1 | Celgene Corporation | $20,400.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222305586 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,516.00 | 01/20/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663840 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $445.00 | 01/20/2025 | Non-covered Recipient Entity Maryland Oncology Hematology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663920 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,620.00 | 01/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1235996085 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $13,210.00 | 01/15/2025 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1235996089 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548973 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1240548978 |
| Principal investigator 1 | Incyte Corporation | $125.00 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548990 |
| Principal investigator 1 | Incyte Corporation | $666.00 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240548996 |
| Principal investigator 1 | Novocure Inc. | $850.00 | 01/15/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856313 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,957.00 | 01/09/2025 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235931063 |